TY - JOUR
T1 - The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer
AU - Zhang, Yan
AU - Mei, Qian
AU - Liu, Yang
AU - Li, Xiang
AU - Brock, Malcolm V.
AU - Chen, Meixia
AU - Dong, Liang
AU - Shi, Lu
AU - Wang, Yao
AU - Guo, Mingzhou
AU - Nie, Jing
AU - Han, Weidong
N1 - Funding Information:
The study was supported by State’s Key Project of Research and Development Plan of China (2016YFC1303504), Science and Technology Planning Project of Beijing City (Z151100003915076) and National Natural Science Foundation of China (31671338, 81472838, 81572914, 81650025, and 81230061).
Funding Information:
The academic advisements of Zhiqiang Wu and Xiaolei Li, and technical assistance of Chao Jia and Wei Li, are gratefully acknowledged. The study was supported by State's Key Project of Research and Development Plan of China (2016YFC1303504), Science and Technology Planning Project of Beijing City (Z151100003915076) and National Natural Science Foundation of China (31671338, 81472838, 81572914, 81650025, and 81230061).
Publisher Copyright:
© 2017 Taylor & Francis Group, LLC.
PY - 2017/9/2
Y1 - 2017/9/2
N2 - Purpose: DNA demethylating agents have shown clinical effectiveness in hematological and solid tumors. This trial tested the safety, efficacy, and treatment outcomes of decitabine-based chemotherapy or combined with immunotherapy in recurrent ovarian cancer patients. Patients and methods: Fifty-five patients with recurrent ovarian cancer were enrolled and 52 were assessable for clinical response and survival. Patients either received 5-d decitabine treatment, followed by reduced-dose of paclitaxel/carboplatin administration (DTC cohort), or the aforementioned regimen combined with cytokine-induced killer cells therapy (DTC+CIK cohort). The primary end point was clinical response rate and progression-free survival (PFS). Secondary evaluation included safety assessment and overall survival (OS). Results: Disease control rate (DCR) and objective response rate (ORR) were 73.91% and 23.91% in disease measurable patients by RECIST criteria, totally 76.92% and 30.77%, including disease non-measurable patients, which were higher in platinum-resistant/refractory patients. Clinical benefits could be associated with the number of DAC treatment cycles and the inclusion of CIK immunotherapy. In DTC+CIK cohort, DCR and ORR reached 100% and 58.30%, respectively. Notably, DTC+CIK treatment in platinum-resistant/refractory patients had an ORR of 87.50%. Consistently, PFS was longer in platinum-resistant/refractory patients comparing with that of platinum-sensitive patients. PFS and OS were 8 and 19 mo in platinum-resistant/refractory patients with DTC+CIK therapy. The most common toxicities were nausea, anorexia, fatigue, neutropenia, and anemia; many of which were grade 1–2. Conclusion: Low-dose DAC/paclitaxel/carboplatin regimen demonstrates disease benefit, especially in patients with platinum-resistant/refractory ovarian cancer, and might show remarkable clinical response when combined with adoptive immunotherapy in platinum-resistant/refractory ovarian cancer patients.
AB - Purpose: DNA demethylating agents have shown clinical effectiveness in hematological and solid tumors. This trial tested the safety, efficacy, and treatment outcomes of decitabine-based chemotherapy or combined with immunotherapy in recurrent ovarian cancer patients. Patients and methods: Fifty-five patients with recurrent ovarian cancer were enrolled and 52 were assessable for clinical response and survival. Patients either received 5-d decitabine treatment, followed by reduced-dose of paclitaxel/carboplatin administration (DTC cohort), or the aforementioned regimen combined with cytokine-induced killer cells therapy (DTC+CIK cohort). The primary end point was clinical response rate and progression-free survival (PFS). Secondary evaluation included safety assessment and overall survival (OS). Results: Disease control rate (DCR) and objective response rate (ORR) were 73.91% and 23.91% in disease measurable patients by RECIST criteria, totally 76.92% and 30.77%, including disease non-measurable patients, which were higher in platinum-resistant/refractory patients. Clinical benefits could be associated with the number of DAC treatment cycles and the inclusion of CIK immunotherapy. In DTC+CIK cohort, DCR and ORR reached 100% and 58.30%, respectively. Notably, DTC+CIK treatment in platinum-resistant/refractory patients had an ORR of 87.50%. Consistently, PFS was longer in platinum-resistant/refractory patients comparing with that of platinum-sensitive patients. PFS and OS were 8 and 19 mo in platinum-resistant/refractory patients with DTC+CIK therapy. The most common toxicities were nausea, anorexia, fatigue, neutropenia, and anemia; many of which were grade 1–2. Conclusion: Low-dose DAC/paclitaxel/carboplatin regimen demonstrates disease benefit, especially in patients with platinum-resistant/refractory ovarian cancer, and might show remarkable clinical response when combined with adoptive immunotherapy in platinum-resistant/refractory ovarian cancer patients.
KW - CIK therapy
KW - decitabine
KW - epigenetic therapy
KW - platinum sensitivity
KW - recurrent ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=85028563236&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028563236&partnerID=8YFLogxK
U2 - 10.1080/2162402X.2017.1323619
DO - 10.1080/2162402X.2017.1323619
M3 - Article
C2 - 28932630
AN - SCOPUS:85028563236
VL - 6
JO - OncoImmunology
JF - OncoImmunology
SN - 2162-4011
IS - 9
M1 - e1323619
ER -